Cargando…
Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study
Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hy...
Autores principales: | Tien, Ni, Wu, Tien-Yuan, Lin, Cheng-Li, Wu, Chia-Jui, Hsu, Chung-Y, Fang, Yi-Jen, Lim, Yun-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234280/ https://www.ncbi.nlm.nih.gov/pubmed/35770006 http://dx.doi.org/10.3389/fmed.2022.910623 |
Ejemplares similares
-
Future of Endoscopy in Inflammatory Bowel Diseases (IBDs)
por: Agrawal, Laksh S, et al.
Publicado: (2022) -
Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
por: Wu, Tien-Yuan, et al.
Publicado: (2023) -
Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017) -
Endoscopic stricturotomy in the treatment of anastomotic strictures in inflammatory bowel disease (IBD) and non-IBD patients
por: Zhang, Long-Juan, et al.
Publicado: (2019) -
The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature
por: Nduma, Basil N, et al.
Publicado: (2023)